The Co-regulatory Networks of Tumor Suppressor Genes, Oncogenes, and MiRNAs in Colorectal Cancer
Overview
Oncology
Authors
Affiliations
Tumor suppressor genes (TSGs) and oncogenes (OG) are involved in carcinogenesis. MiRNAs also contribute to cellular pathways leading to cancer. We use data from 217 colorectal cancer (CRC) cases to evaluate differences in TSGs and OGs expression between paired CRC and normal mucosa and evaluate how TSGs and OGs are associated with miRNAs. Gene expression data from RNA-Seq and miRNA expression data from Agilent Human miRNA Microarray V19.0 were used. We focus on genes most strongly associated with CRC (fold change (FC) of ≥1.5 or ≤0.67) that were statistically significant after adjustment for multiple comparisons. Of the 74 TSGs evaluated, 22 were associated with carcinoma/normal mucosa differential expression. Ten TSGs were up-regulated (FAM123B, RB1, TP53, RUNX1, MSH2, BRCA1, BRCA2, SOX9, NPM1, and RNF43); six TSGs were down-regulated (PAX5, IZKF1, GATA3, PRDM1, TET2, and CYLD); four were associated with MSI tumors (MLH1, PTCH1, and CEBPA down-regulated and MSH6 up-regulated); and two were associated with MSS tumors (PHF6 and ASXL1 up-regulated). Thirteen of these TSGs were associated with 44 miRNAs. Twenty-seven of the 59 OGs evaluated were dysregulated: 14 down-regulated (KLF4, BCL2, SSETBP1, FGFR2, TSHR, MPL, KIT, PDGFRA, GNA11, GATA2, FGFR3, AR, CSF1R, and JAK3), seven up-regulated (DNMT1, EZH2, PTPN11, SKP2, CCND1, MET, and MYC); three down-regulated for MSI (FLT3, CARD11, and ALK); two up-regulated for MSI (IDH2 and HRAS); and one up-regulated with MSS tumors (CTNNB1). These findings suggest possible co-regulatory function between TSGs, OGs, and miRNAs, involving both direct and indirect associations that operate through feedback and feedforward loops.
Natural compounds as regulators of miRNAs: exploring a new avenue for treating colorectal cancer.
Doghish A, Mageed S, Mohammed O, Abdel-Reheim M, Zaki M, Mohamed A Funct Integr Genomics. 2025; 25(1):42.
PMID: 39982533 DOI: 10.1007/s10142-025-01547-8.
Monemi M, Ahmed H, Kareem R, Taher W, Alwan M, Jawad M Int J Mol Cell Med. 2025; 13(4):374-386.
PMID: 39895914 PMC: 11786127. DOI: 10.22088/IJMCM.BUMS.13.4.374.
Identification of a distinctive immunogenomic gene signature in stage-matched colorectal cancer.
Ahluwalia P, Mondal A, Vashisht A, Singh H, Alptekin A, Ballur K J Cancer Res Clin Oncol. 2024; 151(1):9.
PMID: 39673574 PMC: 11646222. DOI: 10.1007/s00432-024-06034-4.
Strategy of combining CDK4/6 inhibitors with other therapies and mechanisms of resistance.
Xue Y, Zhai J Int J Clin Exp Pathol. 2024; 17(7):189-207.
PMID: 39114502 PMC: 11301413. DOI: 10.62347/HGNI4903.
Ding H, Tong J, Lin H, Ping F, Yao T, Ye Z Aging (Albany NY). 2024; 16(9):8070-8085.
PMID: 38728249 PMC: 11132013. DOI: 10.18632/aging.205805.